Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip Minar

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Biorxiv : the Preprint Server for Biology|July 14, 2025
Hybrid Population PK-Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Clinical Pharmacology and Therapeutics|November 5, 2025
Model-Informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Pediatric Quality & Safety|May 12, 2021
Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel DiseaseJennifer Hellmann, Renee K Etter, Lee A Denson, et al.
Inflammatory Bowel Diseases|October 19, 2016
A Low Neutrophil CD64 Index Is Associated with Sustained Remission During Infliximab Maintenance TherapyPhillip Minar, Kimberly Jackson, Yi-Ting Tsai, et al.
The Journal of Pediatrics|May 27, 2023
Racial Disparities in Pediatric Inflammatory Bowel Disease Care: Differences in Outcomes and Health Service Utilization Between Black and White ChildrenJulia Smith, Chunyan Liu, Andrew Beck, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 6, 2023
Acute pancreatitis is associated with gut dysbiosis in childrenChinenye R Dike, Nicholas J Ollberding, Tyler Thompson, et al.
Inflammatory Bowel Diseases|January 3, 2024
Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar PharmacokineticsRuben J Colman, Stephanie A Vuijk, Ron A A Mathôt, et al.
Clinical Pharmacology and Therapeutics|December 23, 2020
Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's DiseaseYe Xiong, Tomoyuki Mizuno, Ruben Colman, et al.
Inflammatory Bowel Diseases|September 18, 2020
Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's DiseaseRuben J Colman, Yi-Ting Tsai, Kimberly Jackson, et al.
Inflammatory Bowel Diseases|May 26, 2020
Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel DiseaseJohn L Lyles, Aditi A Mulgund, Laura E Bauman, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Biorxiv : the Preprint Server for Biology|July 14, 2025
Hybrid Population PK-Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Clinical Pharmacology and Therapeutics|November 5, 2025
Model-Informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Pediatric Quality & Safety|May 12, 2021
Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel DiseaseJennifer Hellmann, Renee K Etter, Lee A Denson, et al.
Inflammatory Bowel Diseases|October 19, 2016
A Low Neutrophil CD64 Index Is Associated with Sustained Remission During Infliximab Maintenance TherapyPhillip Minar, Kimberly Jackson, Yi-Ting Tsai, et al.
The Journal of Pediatrics|May 27, 2023
Racial Disparities in Pediatric Inflammatory Bowel Disease Care: Differences in Outcomes and Health Service Utilization Between Black and White ChildrenJulia Smith, Chunyan Liu, Andrew Beck, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 6, 2023
Acute pancreatitis is associated with gut dysbiosis in childrenChinenye R Dike, Nicholas J Ollberding, Tyler Thompson, et al.
Inflammatory Bowel Diseases|January 3, 2024
Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar PharmacokineticsRuben J Colman, Stephanie A Vuijk, Ron A A Mathôt, et al.
Clinical Pharmacology and Therapeutics|December 23, 2020
Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's DiseaseYe Xiong, Tomoyuki Mizuno, Ruben Colman, et al.
Inflammatory Bowel Diseases|September 18, 2020
Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's DiseaseRuben J Colman, Yi-Ting Tsai, Kimberly Jackson, et al.
Inflammatory Bowel Diseases|May 26, 2020
Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel DiseaseJohn L Lyles, Aditi A Mulgund, Laura E Bauman, et al.
Pageof 5